Zach Jonasson
Managing General Partner @ Phoenix Venture Partners
Seattle, United States
Zach Jonasson is a Series A investor at Phoenix Venture Partners in Seattle focused on Biotechnology and Health Care. Jonasson is a Partner and co-founder of Phoenix Venture Partners (PVP). He brings over 25 years of experience in venture capital and start-ups. He was the co-founder (and initial CEO) of ReForm Biologics, a start-up developing next generation formulations technologies for biotherapeutics, and Crop Enhancement, a start-up developing green coatingsand encapsulants for agriculture. Previously, he was a General Partner and Kauffman Fellow at Seaflower Ventures, where his prior investments included Serenex (acquired), MetaWorks (acquired), and Valeritas (VLRX). Dr. Jonasson led turn-arounds at MetaWorks, which led to the company’s acquisition, and Valeritas, where he successfully reorganized the company around a $70 M series C round to support its product launch. Earlier in his career, while still a doctoral student, Dr. Jonasson was part of the initial five person team at RCM (acquired), where he designed process optimization instrumentation for major chemicals and energy companies, including Eastman Chemical, Shell, and Sempra.Dr. Jonasson earned a BS from Georgetown University, where he was a Rhodes Scholarship Finalist, and an AM and PhD from Harvard University, where he was a Sackler Scholar. He has taught at Harvard Business School and Harvard College. In addition to his investment and board roles at PVP, Dr. Jonasson serves on the board of the Oregon Translational Research and Development Institute (OTRADI), on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), on the Advisory Board for the Oregon Innovation Cluster (OIC), and on the Advisory Board of the Life Sciences Institute at the University of British Columbia.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Zach Jonasson invests in
Stages Zach Jonasson invests in
Countries Zach Jonasson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (42%)
- Health Care 3 (25%)
- Biopharma 2 (17%)
- Life Science 2 (17%)
- SaaS 1 (8%)
Stage
- Series A 5 (42%)
- Series B 2 (17%)
- Seed 1 (8%)
- Series C 1 (8%)
- Series D 1 (8%)
Country
- United States 4 (33%)
- Canada 3 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NanoVation Therapeutics
|
NanoVation Therapeutics provides technologies utilizing lipid nanoparticles for the safe and efficient delivery of nucleic acid tissues. | Seed / Nov 19, 2024 | |
Xandar Kardian
|
Xandar Kardian provides commercially deployed 99.9% 'true' presence detection and people (occupancy) count solutions for smart building applications. It's patented and proprietary occupancy count system is the world's first and only commercial grade system that is able to count from any open space (virtual zones), making foottraffic counting possible in areas that was not possible with traditional cameras. Using micro-vibration patterns emitted from the body (chest movement from breathing, heart beat frequency from the heart (BPM) movement inside the body), XK is able to obtain 95% repetitive accurate RHR and RR measurements continuously. Occupant wellness - either in an office space, factory, hospital, nursing home or residential homes is now possible continuously, autonomously and without using any cameras or wearable devices. | $10M / Series A / Dec 14, 2021 | |
L7 Informatics
|
L7 Informatics provides a workflow management software platform for companies using data-intensive scientific techniques. Advances in next-generation sequencing (NGS) are enabling rapid detection and diagnosis of genetic diseases. It has developed the Enterprise Sequencing Platform (ESP) to accelerate clinical adoption of sequencing and provide aplatform for clinicians to easily track, manage, and interpret patient data. It is the first software designed from the ground-up that fully integrates all the requisite components of NGS data flow management, analysis, and reporting, with auditing capability.It was founded in 2012 and is headquartered in Austin, Texas. | $13M / Series B / Mar 08, 2021 | |
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $70M / Series E / Oct 20, 2020 | |
|
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $10.4M / Series D / Jan 14, 2020 | |
BroadSpot Imaging Corporation
|
BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentallyimprove how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages. | $8.6M / Series A / Oct 09, 2018 | |
|
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $12M / Series C / May 30, 2018 | |
|
BroadSpot Imaging Corporation
|
BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentallyimprove how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages. | Series A / Oct 04, 2017 | |
|
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | Series B / Aug 14, 2017 | |
|
Amber Molecular
|
Creating Emissive Materials for a New Generation of OLEDs | Series A / Apr 25, 2016 | |
| See all 12 investments → | |||
Co-Investors
About Phoenix Venture Partners
Phoenix Venture Partners (PVP) is a venture capital firm that invests in and partners with entrepreneurs to commercialize breakthrough materials science innovations. PVP’s team has a track record of founding, building, and investing in successful materials science start-ups. The firm’s investment strategy is flexible and predicated on assistingentrepreneurs with customer and supply chain partnerships, business development, as well as strategic and operational support. PVP collaborates with a select set of forward-looking global corporations on business development and innovation interests.Phoenix Venture Partners was founded in 2010 and is based in Silicon Valley with satellite offices in Singapore and Cambridge, MA.
Phoenix Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christina Jenkins
Venture Partner
|
|||
Jennifer Wang
CFO
|
|||
Nobuyuki Kambe
Managing General Partner
|
|||
|
Zach Jonasson
Managing General Partner
|
|||
David Soane
Special Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Zach Jonasson invest in?
Zach Jonasson invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Zach Jonasson?
Public channels for Zach Jonasson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Zach Jonasson last invest?
The most recent investment recorded for Zach Jonasson closed in Nov 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
